Newsroom
February 25, 2020
First Prospective Study Shows +RNAinsight™ Identifies More Patients with Increased Risk for Hereditary Cancer Than DNA-Only Testing
The first notable improvement in diagnostic yield for high-risk cancer genes in more than 10 years, +RNAinsight adds RNA genetic testing to DNA multigene panels (Aliso Viejo, CA) February 25, 2020: Ambry Genetics (Ambry), a leading clinical genetic testing lab, announced the publication of a ...
Read More
January 28, 2020
Invicro Scientists Work on Imaging Synaptic Density in Schizophrenia Published in Nature Communications
BOSTON, MA, 28 January 2020 – Invicro LLC, a Konica Minolta company announces that the paper “Synaptic Density Marker SV2A is Reduced in Schizophrenia Patients and Unaffected by Antipsychotics in Rats1” has been published in Nature Communications. Invicro is a global provider of imaging biomarkers, ...
Read More
January 14, 2020
Invicro and Paige Partner to Offer Comprehensive Tissue Biomarker Profiling Services
(BOSTON, MA and NEW YORK, NY) January 14, 2020 — Invicro LLC, a Konica Minolta Company and Paige, Inc., the leader in computational pathology, today announced a strategic alliance to provide integrated pathology solutions to support Pharmaceutical and Biotechnology sponsors with their drug discovery ...
Read More
December 23, 2019
Invicro LLC Announces Dr. Matthew Silva as New Chief Executive Officer and Dr. Jack Hoppin is Named President of Konica Minolta Precision Medicine
(BOSTON, MA) December 23, 2019 — Invicro LLC, a Konica Minolta company, today announces, Dr. Matthew Silva has been appointed as the new Chief Executive Officer. Dr. Silva will assume the day-to-day leadership responsibilities of the Company and will join Invicro’s Board of Directors, effective ...
Read More
December 16, 2019
Ambry Genetics Receives New York State Approval to Offer Paired RNA and DNA Genetic Testing for Hereditary Cancer Risk
+RNAinsight™ is now available for New York patients, and will help identify thousands more patients at increased risk for cancer (Aliso Viejo, CA) December 16, 2019: Ambry Genetics® (Ambry), a leading clinical genetic testing company, announced today that the New York State Clinical Laboratory ...
Read More
December 10, 2019
New Data from Ambry Genetics Showed Concurrent RNA and DNA Testing Identified More Patients with Hereditary Breast Cancer than DNA Testing Alone
Separate data demonstrated that finding mutations that increase risks for breast cancer frequently led clinicians to change their medical recommendations to patients. (Aliso Viejo, CA) December 10, 2019: Researchers at Ambry Genetics (Ambry), a leading clinical genetic testing lab, will announce ...
Read More
December 04, 2019
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Partnership combines Caris’ somatic and Ambry’s germline testing strengths to provide clinicians with unique information about the molecular and genetic components of a patient’s cancer IRVING, Texas and ALISO VIEJO, Calif., December 4, 2019 – Caris Life Sciences®, a leading innovator ...
Read More
November 05, 2019
New Data from Ambry Genetics Show Substantial Increase in Diagnostic Yield, Further Supporting the Routine Use of RNA Genetic Testing for Hereditary Cancer Panels
Based on data from a prospective, nationwide, multi-center pilot, adding RNA genetic testing to DNA testing identified more disease-causing mutations compared to DNA-only testing. Results from a separate study demonstrated that genetic testing results frequently lead to changes in patient care ...
Read More
October 23, 2019
Ambry Genetics Published Data that Finds Adding RNA Genetic Testing Provides More Accurate, Actionable Results for Patients who Receive DNA Testing for Hereditary Cancer Risk
A new study published in JAMA Network Open demonstrates that RNA genetic testing can substantially improve the interpretation of DNA testing results and improve medical care (Aliso Viejo, CA) October 23, 2019: Ambry Genetics® (Ambry), a leading clinical genetics company, announced today the publication ...
Read More
October 15, 2019
New Data from Ambry Genetics Demonstrates Impact of First Major Advancement in Over 10 Years to Increase Diagnostic Yield in Genetic Testing for Hereditary Cancer Risk
In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results. Separate data showed RNA genetic testing’s ability to clarify the interpretation of complex ...
Read More